Health Related Quality of Life After Surgery and Oncological Treatment of Colorectal Liver Metastases A Prospective Multicenter Study
Background: Hepatic resection is the only treatment with potential curative intent for
patients having colorectal liver metastases. Combined with chemotherapy, the overall 5-year
survival is 40-50%. The disease free 5-year survival is about 20%, and about 70% of resected
patients experience recurrence from their disease. Even if surgery is superior all other
treatments, most patients will finally die from their cancer. However; surgery contributes
by adding years of life, and for a minority, a disease free life. There has been much effort
to study predictors for outcome after surgery, but little has been focused on quality of
life following this treatment.
Method: EORTC Validated questionnaire (European Organisation Research of Treatment of
Cancer) version QLQ-C30 (3.0) and QLQ LMC21. The patients fill out the questionnaire before
surgery as a baseline, and then after 3,6 and 12 months after surgery. The investigators
also register important clinicopathological data about each patient prospectively.
Observational Model: Cohort, Time Perspective: Prospective
Health related quality of life after liver resection in combination with chemotherapy
The EORTC board has made validated questionaries with manuals for measuring quality of life. The important focus is to see if and when patients gain their HQoL as they did have before surgery.
12 months after surgery
August Bakke, Professor
Director, Surgical clinic, Haukeland University Hospital, Helse-Bergen HF, N-5020 Bergen, Norway
Norway:National Committee for Medical and Health Research Ethics